Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat and Inosine in Parkinson's Disease
NCT07170475Phase 1Recruiting
- Sponsor
- Fujita Health University
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of febuxostat and inosine in Parkinson's disease (PD) (4 arms), sponsored by Fujita Health University. Primary endpoint: Change in plasma hypoxanthine concentration at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
febuxostatinosine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07170475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170475.